Instrument Inactif

Autres langues Keryx Biopharmaceuticals

Actions

US4925151015

Autres langues

28/12/22	Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS Enter into License Agreement
05/08/19	Keryx Biopharmaceuticals, Inc. Announces Settlement of Auryxia Patent Litigation with Panion & Bf Biotech Inc
05/08/19	Keryx Biopharmaceuticals, Inc., and Panion & BF Biotech, Inc Enters into License Agreement with Par Pharmaceutical, Inc
14/12/18	Keryx Biopharmaceuticals, Inc.(NasdaqCM:KERX) dropped from S&P Biotechnology Select Industry Index
14/12/18	Keryx Biopharmaceuticals, Inc.(NasdaqCM:KERX) dropped from S&P TMI Index
14/12/18	Keryx Biopharmaceuticals, Inc.(NasdaqCM:KERX) dropped from S&P Global BMI Index
13/12/18	Keryx Biopharmaceuticals, Inc. Announces Executive Changes
13/12/18	Keryx Biopharmaceuticals, Inc.(NasdaqGM:KERX) dropped from Russell 2000 Index
13/12/18	Keryx Biopharmaceuticals, Inc.(NasdaqGM:KERX) dropped from Russell 3000 Index
12/12/18	Keryx Biopharmaceuticals, Inc.(NasdaqGM:KERX) dropped from NASDAQ Composite Index
12/12/18	Akebia Therapeutics Inc. (‘Akebia’) completed the acquisition of Keryx Biopharmaceuticals Inc. (‘Keryx’) from Baupost Group Securities LLC (‘Baupost’), Abrams Capital LLC, The Vanguard Group Inc. and other shareholders in a merger of equals transaction.
11/12/18	Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
29/11/18	Keryx Biopharmaceuticals : ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
29/11/18	ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
15/11/18	Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc. Announce Board Changes
15/11/18	Keryx Biopharmaceuticals : Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
08/11/18	Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
08/11/18	Keryx Biopharmaceuticals, Inc. Reports Unaudited and Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018
06/11/18	Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018
02/10/18	Rigrodsky & Long, P.A. Announces Investigation of Keryx Biopharmaceuticals, Inc. Merger
01/10/18	Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference
08/08/18	Keryx Biopharmaceuticals : Announces Second Quarter 2018 Financial Results
08/08/18	Keryx Biopharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2018
08/08/18	Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results
02/08/18	Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018